SM
PBYI icon

Sabby Management’s Puma Biotechnology PBYI Stock Holding History

Sabby Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-626
Closed -$2.33M – 249
2017
Q1 		$2.33M Sell
626
-1,073
-63% -$39.2K 0.13% 79
2016
Q4 		$5.22M Buy
1,699
+1,056
+164% +$45.7K 0.3% 49
2016
Q3 		$4.31M Buy
+643
New +$32.5K 0.16% 84
2015
Q4 		– Sell
-288
Closed -$2.17M – 354
2015
Q3 		$2.17M Buy
288
+5
+2% +$473 0.09% 148
2015
Q2 		$3.3M Sell
283
-365
-56% -$66.1K 0.12% 122
2015
Q1 		$15.3M Buy
648
+232
+56% +$49.6K 0.64% 33
2014
Q4 		$7.87M Buy
416
+182
+78% +$40.4K 0.25% 52
2014
Q3 		$5.58M Buy
234
+190
+432% +$39K 0.21% 62
2014
Q2 		$290K Sell
44
-227
-84% -$16.1K 0.01% 211
2014
Q1 		$2.82M Buy
+271
New +$31.9K 0.16% 88

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sabby Management's PBYI Position: Q2 2017 in Review

Sabby Management sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 10,600 shares — an estimated $394K sold.

Sabby Management first reported a position in PBYI in Q4 2014 and held it in 5 quarters. The position peaked at $3.57M in Q4 2014. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

  • Sabby Management reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 10,600 Puma Biotechnology shares in Q2 2017, an estimated $394K.
  • Sabby Management first reported a position in Puma Biotechnology in Q4 2014 and held it in 5 quarters.
  • Sabby Management's Puma Biotechnology position peaked at $3.57M in Q4 2014.
  • 154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.